Back to search results

Quest AD-Detect Blood Test for Alzheimer's Dementia

This study is looking at whether a blood test called Quest AD-Detect can help doctors find Alzheimer's disease earlier in people who are in the hospital for sudden confusion or brain problems (like delirium or encephalopathy). The study wants to see if this blood test can tell the difference between Alzheimer's and other reasons for confusion. You might be able to join if you are 60 to 90 years old, don't have a dementia diagnosis yet, and are currently in the hospital with new cognitive (thinking) problems. The main goal is to see what percentage of these patients have a positive Alzheimer's biomarker (a sign in the body) detected by the blood test. This study plans to include 30 patients, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific intervention (the blood test). It aims to enroll 30 participants.
What's involved
You would have blood collected for the Quest AD-Detect test while in the hospital. A Neurology Clinic will follow up with you 6 months after your hospitalization to discuss the test results.
Compensation
Not stated in the trial record.
Follow-up
Participants will have a follow-up appointment with the Neurology Clinic 6 months after hospitalization.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07222280

Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy

Recruiting
NAAges 60–90InterventionalDiagnostic
Covenant Health, US
~30 participants
Updated 2025-10-29 on ClinicalTrials.gov
What's tested:Quest AD-Detect blood test

At a glance

Recruiting sites
6 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To show the percentage of patients (21 patients in the study) who presented with a cognitive diagnosis (including but not limited to delirium, encephalopathy, etc.) that have a positive biomarker for Alzheimer's dementia
Measured over From enrollment to 6 month follow up appointment with Neurology Clinic.

Conditions

Alzheimer Dementia
Alzheimer Disease
Delirium Confusional State
Encephalopathy
Cognitive Abnormality

Explore related trials

Alzheimer's DiseaseDeliriumEncephalopathyIntellectual impairment

Where it's being run

6 sites across 1 states
Tennessee6

Study leadership

  • Samuel Moore, MD · PRINCIPAL_INVESTIGATOR · Covenant Health, Canada

Who to contact

Clinical Research Nurse Coordinator
[email protected]
865-331-1337
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ages 60 to 90 years old
No prior diagnosis of dementia
Currently hospitalized with cognitive diagnosis, including but no limited to; delirium, encephalopathy, etc. thought to be secondary to a toxic/metabolic state

Exclusion

Age under 60 years
Prior diagnosis of dementing illness or other organic etiology to cognitive impairment

What this trial measures

  • To show the percentage of patients (21 patients in the study) who presented with a cognitive diagnosis (including but not limited to delirium, encephalopathy, etc.) that have a positive biomarker for Alzheimer's dementiaFrom enrollment to 6 month follow up appointment with Neurology Clinic.

    A Six month follow up with the Neurology clinic to discuss the results of Quest AD Detect (p-tau217), those patients who are found to have a positive outcome will receive additional follow-up in the Neurology clinic (which could include the use of additional lab tests or further diagnostic testing).